Sutro Biopharma Profit Margin

Sutro Biopharma (STRO) currently reports a profit margin of -395.25% as of June 2026. That compares with -199.76% in the prior-year period — down 97.9% year over year. That is below the Healthcare sector average of 13.71%. Use the charts on this page to explore Sutro Biopharma's profit margin history and peer comparisons.

Sutro Biopharma's profit margin decreased from -199.76% to -395.25% — a 97.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sutro Biopharma's profit margin of -395.25% is lower than the Healthcare sector average of 13.71%. That is roughly 2982.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sutro Biopharma's current -395.25% should be judged against Healthcare norms (sector average: 13.71%) and against STRO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -395.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.71%. From there, open related valuation or income-statement pages for Sutro Biopharma, and consider following STRO for alerts when major investors trade the stock.